Brain metastases from melanoma: Is there a role for concurrent temozolomide in addition to whole brain radiation therapy?

Steven E. Schild, Deepti Behl, Svetomir N. Markovic, Paul D. Brown, Jonathan R. Sande, Richard L. Deming, Kendrith M. Rowland, James D. Bearden

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Objectives: This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma. Methods: Seven patients with brain metastases from melanoma were treated on a North Central Cancer Treatment Group (NCCTG) trial (N0274) of TMZ plus WBRT. TMZ was given orally in doses of 200 mg/m2 for 5 days every 4 weeks for up to 8 cycles. WBRT was started on the first day of TMZ and included the delivery of 3750 cGy in 15 fractions. In addition, separately analyzed was a cohort of 53 patients treated at the Mayo Clinic who received WBRT alone (39 patients) or WBRT plus TMZ (14 patients). Results: The median survival of the 7 patients treated on N0274 was 3.6 months with 2 of 7 (29%) failing in brain and 5 of 7 (71%) failing elsewhere. For the other cohort of 53 patients, the median survival was 3.8 months with WBRT alone compared 4.3 months for WBRT plus TMZ (P = 0.5). Conclusions: Patients did not appear to benefit from the addition of TMZ to WBRT for the treatment of their brain metastases. Further improvements in outcome will require research to discover more effective systemic therapy and RT techniques.

Original languageEnglish (US)
Pages (from-to)633-636
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number6
DOIs
StatePublished - Dec 2010

Keywords

  • Brain metastases
  • Combined modality therapy
  • Melanoma
  • Temozolomide
  • Whole brain radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Brain metastases from melanoma: Is there a role for concurrent temozolomide in addition to whole brain radiation therapy?'. Together they form a unique fingerprint.

  • Cite this